The global chronic kidney disease (CKD) market is expected to expand significantly from 2025 to 2034 as rising disease prevalence, increased awareness and demand for early detection and novel treatments fuel growth, according to a new market research. The analysis covers epidemiology, current and future treatment practices and forecasted market size across leading regions including the United States, EU4 nations, the United Kingdom and Japan.
In 2024 the CKD market in the seven major markets (7MM) was estimated at approximately USD 4.8 billion, underpinned by an aging population and high rates of diabetes and hypertension that drive CKD incidence. Around 82 million people were living with CKD in the 7MM in 2024, with diagnosed cases projected to grow over the forecast period. Important companies in the field include Maze Therapeutics, AstraZeneca, Boehringer Ingelheim, Mineralys Therapeutics, ProKidney, Disc Medicine, Regeneron Pharmaceuticals, AION Healthspan, Amgen, Eli Lilly, Bayer AG, Johnson and Johnson, Mitsubishi Tanabe Pharma Corporation, Lexicon Pharmaceuticals, Novo Nordisk, and others.
Emerging therapies in development are expected to broaden treatment options and support market growth. These include combinations such as zibotentan/dapagliflozin and baxdrostat/dapagliflozin from AstraZeneca, vicadrostat plus empagliflozin from Boehringer Ingelheim, as well as novel agents like lorundrostat, rilparencel, DISC‑0974 and vonsetamig. A range of other pipeline candidates are being evaluated for their potential to address unmet needs in CKD management.
Advances in diagnostic biomarkers such as KIM‑1 and NGAL are improving early detection and patient stratification, which may increase the pool of patients benefiting from timely intervention. Expanded indications for existing therapies and the launch of new drugs are also expected to contribute to market dynamics through 2034.
Overall, the research suggests that increasing prevalence, enhanced diagnostic capabilities and the introduction of innovative therapies will collectively support sustained market growth for chronic kidney disease care.
